GLP1R and obesity disorder: For example, semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, has demonstrated reliable weight loss effects in treating obesity and diabetes (Knudsen and Lau, 2019; Davies et al., 2021).